Cabaletta Bio said a trial evaluating its rese-cel therapy showed meaningful early clinical responses for patients with pemphigus vulgaris, an autoimmune skin disorder. The stock gained 27%, to $3.07, ...

Sanofi’s Orano Med-partnered radioligand therapy AlphaMedix achieved all primary efficacy endpoints, which included a measure ...

The drug is under Priority Review by the U.S. Food and Drug Administration (FDA) and has a Prescription Drug User Fee Act (PDUFA) date of June 23, 2025 NEW YORK--(BUSINESS WIRE)--Nuvation Bio Inc.

The human body constantly generates a variety of signals that can be measured from outside the body with wearable devices. These bio-signals—ranging from heart rate to sleep state and blood oxygen ...

(RTTNews) - September 2025 could be a make-or-break month for some biotech stocks, as the companies prepare to release critical clinical trial data. The following are some of the biotech stocks to ...

LONDON & SAN FRANCISCO--(BUSINESS WIRE)--Verdiva Bio Limited (“Verdiva” or “the Company”) a clinical-stage biopharmaceutical company focused on developing innovative therapies for obesity and ...

Instil Bio (TIL) and its partner ImmuneOnco have been doing well to advance their potential best-in-class PD-1/VEGF bispecific antibody AXN-2510 for the treatment of patients with solid tumors. The ...

Upstream Bio's IPO raised ~$293m, focusing on developing verekitug, a unique TSLP receptor antagonist for severe respiratory disorders, now in Phase 2 trials. The company has a strong cash position of ...

Vor Bio announces a $55.6 million PIPE to fund clinical trials and expects to report updated data in 2025. Vor Bio, a clinical-stage cell and genome engineering company, announced a securities ...